TABLE 3.

Association between PCOS types and venous thromboembolism stratified by age and OCP use

PCOS type	Age groups
	18–24 y	25–34 y	35–45 y
OCP use = yes,a aOR (95% CI)b
No PCOSc	Reference	Reference	Reference
Any PCOSd	2.89 (2.17–3.85)	1.98 (1.66–2.37)	1.79 (1.51–2.12)
Phenotype Ae	3.11 (2.22–4.36)	1.69 (1.33–2.16)	1.83 (1.51–2.22)
Phenotype Bf	4.58 (2.17–9.66)	1.53 (0.68–3.41)	1.41 (0.58–3.39)
Phenotype Cg	1.07 (0.40–2.87)	2.24 (1.66–3.03)	1.65 (1.12–2.44)
Phenotype Dh	3.23 (1.20–8.64)	2.89 (1.74–4.82)	1.69 (0.80–3.57)
OCP use = no,i aOR (95% CI)b
No PCOSc	Reference	Reference	Reference
Any PCOSd	3.76 (2.63–5.38)	2.70 (2.29–3.18)	2.18 (1.90–2.50)
Phenotype Ae	2.60 (1.47–4.59)	2.79 (2.24–3.48)	2.02 (1.71–2.38)
Phenotype Bf	6.37 (2.36–17.23)	3.02 (1.57–2.84)	2.20 (1.14–4.26)
Phenotype Cg	5.26 (3.09–8.94)	2.36 (1.78–3.13)	2.54 (1.91–3.36)
Phenotype Dh	2.36 (0.33–16.82)	3.05 (1.63–5.70)	3.03 (1.67–5.51)

aOR, adjusted odds ratio; CI, confidence interval; OCP, oral contraceptive pills; PCOS, polycystic ovary syndrome.

^aGroup of women who had ≥1 filled oral contraceptive prescription during study period;

^bMultivariate logistic regression model was adjusted for pregnancy, region, diabetes, and obesity;

^cWomen without any PCOS phenotype;

^dWomen with any PCOS phenotype;

^eWomen with clinical hyperandrogenism and menstrual or ovulatory dysfunction, or both;

^fWomen with hyperandrogenism and polycystic ovaries;

^gWomen with menstrual or ovulatory dysfunction, or both, and polycystic ovaries;

^hWomen with clinical hyperandrogenism; menstrual or ovulatory dysfunction, or both; and polycystic ovaries;

ⁱGroup of women who did not have ≥1 filled oral contraceptive prescription during study period.

Okoroh. Polycystic ovary syndrome and venous thromboembolism. Am J Obstet Gynecol 2012.